SIR -The insertion (I)/deletion (D) polymorphism of the angiotensin I-converting enzyme (ACE) gene seems to influence therapeutic outcome in patients suffering from unipolar major depression.
ACE is involved in blood pressure regulation via the renin-angiotensin-cascade. It is also expressed in the central nervous system, where its primary function comprises degradation of neuropeptides including substance P (SP). Because of the possible antidepressant effects of SP antagonists, 1 and the decrease of cerebral SP content after monoamine reuptake inhibitors, 2,3 the influence of SP on both pathophysiology and the relief of depression has been hypothesized repeatedly. 4 About 50% of the interindividual variability of ACE concentration is determined by an I/D-polymorphism 5, 6 in the ACE gene. Since the D-allele was associated with higher ACE levels 7 and higher neuropeptide degradation capabilities, this might influence therapeutic efficacy. Moreover, an association between the D/D-genotype and affective disorders was found in Japanese patients. 8 The present study investigated whether this finding could be replicated in European patients and whether the ACE gene variants might have any impact on the outcome of antidepressive therapies.
Ninety-nine unrelated patients with unipolar major depression (DSM-IV) and 99 age-and sex-matched healthy controls from the general population were investigated. All study participants were Caucasians from southern Germany. Controls were screened for psychiatric disorders (Structured Clinical Interview for DSM-IV) and familial loading (SADS Family History form) to exclude those with first degree affected members. Psychiatric ratings in patients included the Hamilton rating scale for depression (HAM-D17) and the clinical global impression scale (CGI, Item 1 -severity of disease). Patients received different treatments (n = 23 tricyclic anti-depressants, 43 mirtazapine, 12 selective serotonin reuptake inhibitors, 10 venlafaxine, 17 electroconvulsive therapy, 23 repetitive transcranial magnetic stimulation, 29 combinations). Genotyping of Categorical variables were compared using the twosided Fisher's Exact test. We compared differences between I/I-homozygotes and D-allele carriers in numerical variables using the Student's t-test. Presup-posing an ␣ of 0.05 with 18 patients (homozygous insertion), a satisfactory power of 0.84 was reached.
Demographic, genetic and clinical data are summarised in Table 1 . We were unable to replicate the previous finding 8 since we observed no significant differences in genotype or allelic distributions between patients and controls (both followed the Hardy-Weinberg Equilibrium). Ethnic differences or differences in patient selection between both studies might be responsible for these discrepancies. 9 No significant differences in genotypes or allele frequencies were found with respect to treatment procedures. A divergent clinical outcome was observed in that, after 4 weeks of treatment, D-allele carriers showed significantly lower HAM-D17 scores (P Ͻ 0.0001), remitted more often (HAM-D17 Ͻ9; D/D+I/D:I/I = 18:1; P = 0.049) and had a significantly shorter duration of hospitalisation (P = 0.020). Also, the number of treatment alterations during hospitalisation was significantly higher in I/I-genotypes. Thus, the Dallele might positively influence the onset of therapeutic efficacy. Homozygosity for the I-allele seems to be associated with delayed response.
Since, in functional studies, ACE allele-D was associated with increased neuropeptide degradation, 10 increased SP concentrations might be responsible for the delayed effect on I/I-genotypes. This, however, has not yet been proven; SP levels were not controlled in this study and the role of SP in the treatment of depression still has to be clarified.
Although therapeutic outcome in different genotypes cannot yet be related to the diversity of medication, our results give first hints that variants in the ACE gene could contribute to differential drug response. Further studies will have to clarify whether this effect is related to different drugs or a common feature of antidepressant treatment. In addition to association studies, family studies might help to further clarify the relationship between treatment response as a complex phenotype and ACE gene polymorphism. Mutation screening of the KCNN3 gene reveals a rare frameshift mutation SIR -Chandy and colleagues 1 reported association between schizophrenia and moderately large alleles of a CAG repeat in the KCNN3 gene encoding hKCa3, a calcium-activated potassium channel. Although others have reported similar findings, most have not replicated this finding. 2 However, recently, Brzustowicz and colleagues 3 have reported linkage between schizophrenia (maximum heterogeneity lod score of 6.5) and chromosome 1q21-22. As KCNN3 also maps to 1q21, 4 it can be considered a positional candidate gene for schizophrenia.
To allow further investigation of KCNN3, we have screened its genomic sequence for other sequence variants using denaturing high performance liquid chromatography (DHPLC). 5 We found two synonymous polymorphisms and a frameshift mutation in exon 1 that is predicted to result in a truncated protein. We tested this variant for association in a sample of 184 individuals of British Caucasian origin diagnosed with DSM-IV schizophrenia, and 184 matched blood donor controls. Furthermore, we also genotyped 93 affected individuals from the 22 pedigrees in the study that yielded strong evidence for linkage to 1q21-22. 3 No further chromosome carrying this mutation were found.
Each exon of KCNN3 was amplified in a series of 10 fragments of size ranging between 158 and 497 bp, using unpublished data concerning its genomic structure (Morris-Rosendahl, unpublished). Amplified sequence included the complete cDNA sequence of the KCNN3 except bases 410-484. These lie between the two CAG repeat arrays in exon 1 and the fragment is too small for DHPLC analysis without the inclusion of the repetitive sequence. DHPLC was performed based upon a protocol that results in detection of 95-100% of mutations. 6 Where DHPLC analysis suggested that any subject was heterozygous, the PCR products from all 14 cases were sequenced using ABI PRISM BigDye Terminator Cycle Sequencing Kits. In order to give an estimate of allele frequencies, the exons with polymorphisms in cases were also sequenced in 13 blood donor controls. The screening set for DHPLC consisted of 14 unrelated subjects meeting DSM-IV criteria for schizophrenia. Details of primers, PCR conditions, and DHPLC analysis are available on request.
We detected: (i) a 4-bp deletion 1137 1140delGTGA in exon 1 (del 1/28 chromosomes in cases, 0/26 chromosomes in controls); (ii) a g.1333TϾC in exon 3 (T allele 8/28 chromosomes in cases and 8/26 in controls); and (iii) a tri-allelic polymorphism g.1378AϾCϽG also in exon 3 (A allele, 3/28 chromosomes in cases, 7/26 in controls; G allele 13/28 in cases, 9/26 in controls; C allele 12/28 in cases, 10/26 in controls). All changes from the reference sequence (GenBank AF031815) in exon 3 are synonymous.
Because they are synonymous, the polymorphisms
